{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024318", "CSN": null, "TRF": "ORD_1485630_01", "MRN": "44954598", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1214406", "clinicalId": "1215776", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1485630_01", "SampleName": "US1422354.01", "Version": "0", "Sample": {"FM_Id": "ORD_1485630_01", "SampleId": "US1422354.01", "BlockId": "nan", "TRFNumber": "ORD_1485630_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_10_24", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97975", "MRN": "44954598", "FullName": "\u6797\u5ef6\u5a01", "FirstName": "Yen_Wei", "LastName": "Lin", "SubmittedDiagnosis": "Metastatic seminoma (From S111-17598)", "Gender": "Male", "DOB": "1993_03_30", "OrderingMD": "\u5f35\u5bb6\u9298", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_10_20", "ReceivedDate": "2022-11-10 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Germ cell tumor"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "12", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "BARD1", "isVUS": "true", "variantName": "G82V"}, {"geneName": "C11orf30 (EMSY)", "isVUS": "true", "variantName": "S1076G"}, {"geneName": "CEBPA", "isVUS": "true", "variantName": "A358G"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "E133K"}, {"geneName": "FLT1", "isVUS": "true", "variantName": "P470H"}, {"geneName": "KDR", "isVUS": "true", "variantName": "splice site 1092_1G>T"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "V670G"}, {"geneName": "PIK3C2B", "isVUS": "true", "variantName": "H1145L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "RAD54L", "Include": "true", "Alterations": {"Alteration": {"Name": "C391fs*1", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "C391fs*1"}}, "Interpretation": "RAD54L encodes a member of the SNF2/SWI2 superfamily and forms part of the RAD52 complex involved in recombination and DNA repair in response to ionizing radiation (Kanaar et al., 1996; 8805304, Sigurdsson et al., 2002; 12205100, Swagemakers et al., 1998; 9774452, van Veelen et al., 2005; 15914205). Alterations leading to disruption of critical domains with RAD54L are predicted to enhance genomic instability (Smirnova et al., 2004; 15056673). Alterations such as seen here may disrupt RAD54L function or expression (Smirnova et al., 2004; 15056673, Matsuda et al., 1999; 10362365, Golub et al., 1997; 9321665, Spies et al., 2016; 27264870, Goyal et al., 2018; 29295984, Burgess et al. 2013; 24376557, Lengert et al., 2019; 30961891). RAD54L alterations are rare in cancer (cBio_Zehir et al., 2017; 28481359). Loss of heterozygosity (LOH) at chromosomal region 1p32_34, in which RAD54L resides, has been reported as a frequent event in breast cancer (Rasio et al., 1997; 9192813), oligodendroglioma (Bello et al., 2000; 10640146), nontypical meningioma (Kim et al., 2009; 19347254, Leuraud et al., 2000; 11263500, Lopez_Gines et al., 2004; 14734222, Mendiola et al., 1999; 10326867), and parathyroid adenoma (Carling et al., 1999; 10449612), but it is not clear whether RAD54L loss of function is pathogenic in these cases. Increased RAD54L expression was reported in NSCLC samples in response to increased mutation rate (V\u00e4lk et al., 2010; 21412013) and also in castration_resistant prostate cancer (CRPC) cells (Li et al., 2017; 28536297). RAD54L polymorphisms have been associated with increased risk of developing meningioma (Leone et al., 2003; 12614485), glioma (Zhang et al., 2016; 26514363), and decreased overall survival (P<0.004) in patients with potentially resectable pancreatic adenocarcinoma (Li et al., 2006; 16520463). Germline mutations of RAD54L has been associated with increased risk of gastric cancer (Li et al., 2013; 23504502) but not lymphoid malignancies (Shinozuka et al., 2015; 26743341). There are no therapies available that directly target RAD54L. Limited clinical evidence in ovarian cancer (O Malley et al., 2017; AACR Abstract LB_A12, Swisher et al., 2017; 27908594) and prostate cancer (de Bono et al., 2020; 32343890) indicates that RAD54L inactivation may confer sensitivity to PARP inhibitors.", "Include": "true", "ClinicalTrialNote": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT04991480", "Include": "true"}, {"nctId": "NCT04901702", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Compared to other tumor types, germ cell tumors (GCTs) have been reported to have a low TMB (mean 0.51 mutations per megabase [muts/Mb] as measured in tissue), with a similar mutation rate reported for seminoma (0.50 muts/Mb) and non_seminoma (0.49 muts/Mb) tumors (Litchfield et al., 2015; 25609015). Published data investigating the prognostic implications of TMB in germ cell tumors are limited (PubMed, Sep 2022). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI positivity at any level has been reported in 0_31% (n = 17_188) of testicular germ cell tumors (GCTs) (Lothe et al., 1993; 8261392, Murty et al., 1994; 8033127, Huddart et al., 1995; 7669575, Faulkner and Friedlander, 2000; 11006028, Devouassoux_Shisheboran et al., 2001; 11719586, Velasco et al., 2004; 15492498, Olasz et al., 2005; 16309235, Vladu\u0161i\u0107 et al., 2014; 25075023, C\u00e1rcano et al., 2016; 27153176) and in 33% (12/36) of ovarian GCTs (Faulkner and Friedlander, 2000; 11006028). Within testicular GCTs, 12_31% of cases (n = 17_51) have been classified as having low_level MSI (MSI_L) and 69_100% (n = 17_133) have been classified as MSS (Devouassoux_Shisheboran et al., 2001; 11719586, Olasz et al., 2005; 16309235, C\u00e1rcano et al., 2016; 27153176), with MSI_high (MSI_H) rarely reported; one study identified MSI_L in 6% (6/100) and MSI_H in 0% (0/100) of unselected testicular GCTs, and MSI_L in 6% (2/35) and MSI_H in 26% (9/35) of chemotherapy_resistant cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622). The significance of MSI in the context of GCTs is not well established (PubMed, Nov 2021). One study reported MSI_H to be significantly more frequent in chemotherapy_resistant than unselected testicular GCT cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622), and some studies have associated MSI positivity with reduced PFS and/or increased risk of recurrence (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622, Velasco et al., 2004; 15492498, Velasco et al., 2008; 18076065); however, another study found no correlation between MSI status and clinicopathologic features, including chemotherapy sensitivity and outcome (Olasz et al., 2005; 16309235). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)", "NCTID": "NCT04644068", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Tel Aviv (Israel), Beer_Sheva (Israel)", "NCTID": "NCT03742895", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee", "NCTID": "NCT04497116", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PARP, Pol theta", "Locations": "London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida", "NCTID": "NCT04991480", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD54L", "Alteration": "C391fs*1", "Title": "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma", "StudyPhase": "PHASE 1/2", "Target": "TOP1, PARP", "Locations": "Tennessee", "NCTID": "NCT04901702", "Note": "RAD54L inactivation may predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "8805304", "FullCitation": "Kanaar R, et al. Curr. Biol. (1996) pmid: 8805304", "Include": "true"}, {"number": "1", "ReferenceId": "12205100", "FullCitation": "Sigurdsson S, et al. J. Biol. Chem. (2002) pmid: 12205100", "Include": "true"}, {"number": "2", "ReferenceId": "9774452", "FullCitation": "Swagemakers SM, et al. J. Biol. Chem. (1998) pmid: 9774452", "Include": "true"}, {"number": "3", "ReferenceId": "15914205", "FullCitation": "van Veelen LR, et al. Mutat. Res. (2005) pmid: 15914205", "Include": "true"}, {"number": "4", "ReferenceId": "15056673", "FullCitation": "Smirnova M, et al. J. Biol. Chem. (2004) pmid: 15056673", "Include": "true"}, {"number": "5", "ReferenceId": "10362365", "FullCitation": "Matsuda M, et al. Oncogene (1999) pmid: 10362365", "Include": "true"}, {"number": "6", "ReferenceId": "9321665", "FullCitation": "Golub EI, et al. Nucleic Acids Res. (1997) pmid: 9321665", "Include": "true"}, {"number": "7", "ReferenceId": "27264870", "FullCitation": "Spies J, et al. Mol. Cell (2016) pmid: 27264870", "Include": "true"}, {"number": "8", "ReferenceId": "29295984", "FullCitation": "Goyal N, et al. Nat Commun (2018) pmid: 29295984", "Include": "true"}, {"number": "9", "ReferenceId": "30961891", "FullCitation": "Lengert N, et al. Biophys. J. (2019) pmid: 30961891", "Include": "true"}, {"number": "10", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "11", "ReferenceId": "9192813", "FullCitation": "Rasio D, et al. Cancer Res. (1997) pmid: 9192813", "Include": "true"}, {"number": "12", "ReferenceId": "10640146", "FullCitation": "Bello MJ, et al. Cancer Genet. Cytogenet. (2000) pmid: 10640146", "Include": "true"}, {"number": "13", "ReferenceId": "19347254", "FullCitation": "Kim NR, et al. J. Neurooncol. (2009) pmid: 19347254", "Include": "true"}, {"number": "14", "ReferenceId": "11263500", "FullCitation": "Leuraud P, et al. J. Neurooncol. (2000) pmid: 11263500", "Include": "true"}, {"number": "15", "ReferenceId": "14734222", "FullCitation": "Lopez_Gines C, et al. Cancer Genet. Cytogenet. (2004) pmid: 14734222", "Include": "true"}, {"number": "16", "ReferenceId": "10326867", "FullCitation": "Mendiola M, et al. Mol. Carcinog. (1999) pmid: 10326867", "Include": "true"}, {"number": "17", "ReferenceId": "10449612", "FullCitation": "Carling T, et al. Int. J. Cancer (1999) pmid: 10449612", "Include": "true"}, {"number": "18", "ReferenceId": "21412013", "FullCitation": "V\u00e4lk K, et al. Oncology (2010) pmid: 21412013", "Include": "true"}, {"number": "19", "ReferenceId": "28536297", "FullCitation": "Li L, et al. Sci Signal (2017) pmid: 28536297", "Include": "true"}, {"number": "20", "ReferenceId": "12614485", "FullCitation": "Leone PE, et al. BMC Cancer (2003) pmid: 12614485", "Include": "true"}, {"number": "21", "ReferenceId": "26514363", "FullCitation": "Zhang H, et al. J. Neurooncol. (2016) pmid: 26514363", "Include": "true"}, {"number": "22", "ReferenceId": "16520463", "FullCitation": "Li D, et al. J. Clin. Oncol. (2006) pmid: 16520463", "Include": "true"}, {"number": "23", "ReferenceId": "23504502", "FullCitation": "Li WQ, et al. Carcinogenesis (2013) pmid: 23504502", "Include": "true"}, {"number": "24", "ReferenceId": "26743341", "FullCitation": "Shinozuka K, et al. Biol. Blood Marrow Transplant. (2016) pmid: 26743341", "Include": "true"}, {"number": "25", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "26", "ReferenceId": "32343890", "FullCitation": "de Bono J, et al. N. Engl. J. Med. (2020) pmid: 32343890", "Include": "true"}, {"number": "27", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "28", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "29", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "30", "ReferenceId": "8261392", "FullCitation": "Lothe RA, et al. Cancer Res. (1993) pmid: 8261392", "Include": "true"}, {"number": "31", "ReferenceId": "8033127", "FullCitation": "Murty VV, et al. Cancer Res. (1994) pmid: 8033127", "Include": "true"}, {"number": "32", "ReferenceId": "7669575", "FullCitation": "Huddart RA, et al. Br. J. Cancer (1995) pmid: 7669575", "Include": "true"}, {"number": "33", "ReferenceId": "11006028", "FullCitation": "Faulkner SW, et al. Gynecol. Oncol. (2000) pmid: 11006028", "Include": "true"}, {"number": "34", "ReferenceId": "11719586", "FullCitation": "Devouassoux_Shisheboran M, et al. Mol. Hum. Reprod. (2001) pmid: 11719586", "Include": "true"}, {"number": "35", "ReferenceId": "15492498", "FullCitation": "Velasco A, et al. Cancer Biol. Ther. (2004) pmid: 15492498", "Include": "true"}, {"number": "36", "ReferenceId": "16309235", "FullCitation": "Olasz J, et al. Anticancer Res. () pmid: 16309235", "Include": "true"}, {"number": "37", "ReferenceId": "25075023", "FullCitation": "Vladu\u0161i\u0107 T, et al. Anticancer Res. (2014) pmid: 25075023", "Include": "true"}, {"number": "38", "ReferenceId": "27153176", "FullCitation": "C\u00e1rcano FM, et al. Andrology (2016) pmid: 27153176", "Include": "true"}, {"number": "39", "ReferenceId": "12019150", "FullCitation": "Mayer F, et al. Cancer Res. (2002) pmid: 12019150", "Include": "true"}, {"number": "40", "ReferenceId": "19289622", "FullCitation": "Honecker F, et al. J. Clin. Oncol. (2009) pmid: 19289622", "Include": "true"}, {"number": "41", "ReferenceId": "18076065", "FullCitation": "Velasco A, et al. Int. J. Cancer (2008) pmid: 18076065", "Include": "true"}, {"number": "42", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "43", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "44", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "45", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "46", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "47", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "48", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "49", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "50", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "51", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "52", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "53", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "54", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "55", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "56", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "57", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "58", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "59", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "60", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "61", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "62", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "63", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "64", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "65", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "66", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "67", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "68", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "69", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "70", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "71", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "72", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "73", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "74", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "75", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "76", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "77", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "78", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "79", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "80", "ReferenceId": "25609015", "FullCitation": "Litchfield K, et al. Nat Commun (2015) pmid: 25609015", "Include": "true"}, {"number": "81", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "82", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "83", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "84", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "85", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_11_01 16:03:24", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "TESTIS", "disease_ontology": "Testis germ cell tumor (seminoma)", "flowcell_analysis": "2000024250", "gender": "male", "pathology_diagnosis": "Seminoma", "pipeline_version": "v3.15.0", "purity_assessment": "14.0", "specimen": "ORD_1485630_01*US1422354.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1485630_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1422354.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0017", "cds_effect": "1092_1G>T", "depth": "2858", "equivocal": "false", "functional_effect": "splice", "gene": "KDR", "percent_reads": "0.17", "position": "chr4:55976734", "protein_effect": "splice site 1092_1G>T", "status": "unknown", "strand": "_", "transcript": "NM_002253", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.3211", "cds_effect": "1092_1093insCGAGACGCTGCTGCTAGTGAGGCAGACAGGCAGCTAGGAGAGGAGCGGCTGCGGGAGCTCACCAGCATTGTGAATAGGTAATGACCTTAAGC", "depth": "1694", "equivocal": "false", "functional_effect": "frameshift", "gene": "RAD54L", "percent_reads": "32.11", "position": "chr1:46736380", "protein_effect": "C391fs*1", "status": "likely", "strand": "+", "transcript": "NM_003579", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.4935", "cds_effect": "3434A>T", "depth": "841", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2B", "percent_reads": "49.35", "position": "chr1:204408145", "protein_effect": "H1145L", "status": "unknown", "strand": "_", "transcript": "NM_002646", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.467", "cds_effect": "245G>T", "depth": "713", "equivocal": "false", "functional_effect": "missense", "gene": "BARD1", "percent_reads": "46.7", "position": "chr2:215657140", "protein_effect": "G82V", "status": "unknown", "strand": "_", "transcript": "NM_000465", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.5367", "cds_effect": "1073C>G", "depth": "1267", "equivocal": "false", "functional_effect": "missense", "gene": "CEBPA", "percent_reads": "53.67", "position": "chr19:33792248", "protein_effect": "A358G", "status": "unknown", "strand": "_", "transcript": "NM_004364", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.5036", "cds_effect": "1409C>A", "depth": "965", "equivocal": "false", "functional_effect": "missense", "gene": "FLT1", "percent_reads": "50.36", "position": "chr13:29001323", "protein_effect": "P470H", "status": "unknown", "strand": "_", "transcript": "NM_002019", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.4667", "cds_effect": "397G>A", "depth": "962", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "46.67", "position": "chr2:212812179", "protein_effect": "E133K", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.5298", "cds_effect": "2009T>G", "depth": "1744", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "52.98", "position": "chr3:49934990", "protein_effect": "V670G", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"allele_fraction": "0.5067", "cds_effect": "3226A>G", "depth": "1202", "equivocal": "false", "functional_effect": "missense", "gene": "EMSY", "percent_reads": "50.67", "position": "chr11:76255819", "protein_effect": "S1076G", "status": "unknown", "strand": "+", "transcript": "NM_020193", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "43", "status": "unknown", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"organism": "HHV_8", "reads_per_million": "23", "status": "unknown", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}, {"organism": "HHV_4", "reads_per_million": "54", "status": "unknown", "dna_evidence": {"sample": "SQ_US1422354.01_1"}}]}}}}}